Walleye Capital
TNGX icon

Walleye Capital’s Tango Therapeutics TNGX Stock Holding History

Walleye Capital’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-211,797
Closed -$290K – 5040
2025
Q1 		$290K Sell
211,797
-75,255
-26% -$185K ﹤0.01% 2980
2024
Q4 		$887K Buy
287,052
+144,476
+101% +$671K ﹤0.01% 2484
2024
Q3 		$1.1M Buy
+142,576
New +$1.36M ﹤0.01% 2563
2024
Q2 		– Sell
-13,172
Closed -$105K – 6014
2024
Q1 		$105K Sell
13,172
-8,990
-41% -$96.4K ﹤0.01% 4373
2023
Q4 		$219K Buy
+22,162
New +$192K ﹤0.01% 3622
2023
Q1 		– Sell
-289,867
Closed -$2.1M – 4368
2022
Q4 		$2.1M Sell
289,867
-114,780
-28% -$807K 0.04% 554
2022
Q3 		$1.47M Buy
+404,647
New +$1.73M 0.03% 720
2021
Q4 		– Sell
-41,415
Closed -$535 – 2320
2021
Q3 		$535 Buy
+41,415
New +$496K 0.02% 761

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

Walleye Capital's TNGX Position: Q2 2025 in Review

Walleye Capital sold out of Tango Therapeutics (TNGX) in Q2 2025, closing a stake of 211,797 shares — an estimated $290K sold.

Walleye Capital first reported a position in TNGX in Q3 2021 and held it in 8 quarters. The position peaked at $2.1M in Q4 2022. 115 funds tracked by Wall St. Rank hold TNGX as of Q2 2025.

  • Walleye Capital reported no remaining Tango Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 211,797 Tango Therapeutics shares in Q2 2025, an estimated $290K.
  • Walleye Capital first reported a position in Tango Therapeutics in Q3 2021 and held it in 8 quarters.
  • Walleye Capital's Tango Therapeutics position peaked at $2.1M in Q4 2022.
  • 115 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.